You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(6160.HK)漲近4% 替雷利珠單抗美國上市申請獲FDA受理
格隆匯 09-13 15:32
格隆匯9月13日丨百濟神州(6160.HK)一度漲近4%報215.8港元,市值逾2600億港元。公司今日宣佈,美國食品藥品監督管理局(FDA)已受理其抗PD-1抗體藥物百澤安®(替雷利珠單抗注射液)的新藥上市申請(BLA),用於治療既往經系統治療後不可切除、複發性局部晚期或轉移性食管鱗狀細胞癌(ESCC)患者。此舉意味着百濟神州的替雷利珠單抗邁出了出海的重要一步。據悉,這款產品已以22億美元授權諾華,在諾華加持之下,前景可期。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account